A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

Study Overview

To assess the safety and tolerability of TTX-080

• IRB Number: 12189
• Research Study Identifier: TX11413
• Principal Investigator: Greg Durm, MD